A phase II study of the efficacy and toxicity of alemtuzumab for the therapy of human T cell lymphotrophic virus-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATL) This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results